Business Wire

NJ-DAIICHI-SANKYO

Share
Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials

Updated results from the TROPION-PanTumor01 phase 1 trial showed datopotamab deruxtecan (Dato-DXd) continued to demonstrate encouraging responses in patients with heavily pretreated metastatic triple negative breast cancer (TNBC) and disease progression following standard treatment. Results were presented today as a poster presentation (Abstract #P6-10-03) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Approximately 15% of breast cancers are considered triple negative and are associated with higher disease recurrence and worse prognosis compared to other breast cancer subtypes.1,2 It is estimated that only 12% of patients with metastatic TNBC survive five years after diagnosis and median overall survival is between 12 to 18 months.1,3

In the TNBC cohort of TROPION-PanTumor01 (n=44) where patients previously received a median of three lines of treatment for metastatic disease, datopotamab deruxtecan demonstrated an objective response rate (ORR) of 32%, including one complete response (CR), 13 partial responses (PRs) and 18 cases of stable disease (SD) as assessed by blinded independent central review (BICR). In a subgroup of 27 patients who had not been previously treated with topoisomerase I inhibitor-based ADCs, the ORR was 44% including one CR, 11 PRs and 10 cases of SD. The median duration of response (DoR) was 16.8 months (95% confidence interval [CI]: 5.6-NE) across patient groups.

“Triple negative breast cancer is the most aggressive subtype of breast cancer with the average survival rate of less than 18 months for patients with pretreated metastatic disease,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Associate Professor of Medicine at Harvard Medical School. “The durable tumor response and disease control seen with datopotamab deruxtecan in patients with pretreated triple negative breast cancer are encouraging, particularly in those patients who had not received previous treatment with topoisomerase I inhibitor-based antibody drug conjugate.”

In the overall cohort, datopotamab deruxtecan demonstrated median progression-free survival (PFS) of 4.4 months (95% CI: 3.0-7.3) and median overall survival (OS) of 13.5 months (95% CI: 10.1-16.3). In the subgroup of patients who had not been previously treated with a topoisomerase I inhibitor, median PFS and OS were 7.3 months (95% CI: 3.0-18.0) and 14.3 months (95% CI: 10.5-NE), respectively. The disease control rate (DCR) was consistent across the overall cohort and previously untreated subgroup at 80% and 81%, respectively.

The safety profile of datopotamab deruxtecan was consistent with previously reported data with no new safety signals identified. The most common grade 3 or higher treatment-emergent adverse events (TEAEs) were stomatitis (11%), decreased lymphocyte count (7%), fatigue (7%), vomiting (5%), anemia (2%), decreased neutrophil count (2%) and nausea (2%). Serious TEAEs were reported in nine patients (20.5%). Treatment discontinuations occurred in one patient (2%) due to grade 1 pneumonitis, which was adjudicated as not treatment-related interstitial lung disease (ILD). No cases of ILD were observed. No cases of febrile neutropenia or grade 3 or higher diarrhea were observed.

“Five-year survival rates for previously treated metastatic triple negative breast cancer are significantly lower than other subtypes of breast cancer, underscoring the need for new, durable therapies,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo. “We are working with urgency and care to evaluate datopotamab deruxtecan in multiple treatment settings in phase 3 trials, including the TROPION-Breast02 first-line phase 3 trial in patients with locally recurrent inoperable or metastatic triple negative breast cancer not candidates for anti-PD-L1 therapy.”

“The median duration of response of nearly 17 months seen in the TROPION-PanTumor01 trial in these patients reinforces the potential of datopotamab deruxtecan to treat this persistent disease,” said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. “These results, along with the promising clinical response in combination with durvalumab seen in the BEGONIA trial, underscore the potential role of this TROP2 directed antibody drug conjugate for patients with triple negative breast cancer as both a monotherapy and in combinations.”

Patients in the TROPION-PanTumor01 trial were heavily pretreated, receiving a median of three prior regimens in the metastatic setting (range, 1-10). Prior treatments included taxanes (93%), anthracyclines (75%), capecitabine (61%), platinum-based chemotherapy (52%), immunotherapy (45%), topoisomerase I inhibitor-based ADCs (32%) and PARP inhibitors (18%). As of data cut-off on July 22, 2022, three patients remained on study treatment.

Summary of TROPION-PanTumor01 Results in Metastatic TNBC

Efficacy Measure

All TNBC Patients
[n=44 (6 mg/kg, n=42;
8 mg/kg, n=2)]

 

Patients Without Prior Topoisomerase I
Inhibitor-Based ADC
[n=27 (6 mg/kg, n=25; 8 mg/kg, n=2)]

Confirmed ORR, %i,ii

32% (n=14)

44% (n=12)

CR, %

2% (n=1)

4% (n=1)

PR, %

30% (n=13)

41% (n=11)

SD, %

41% (n=18)

37% (n=10)

Non-CR/non-PD, %

7% (n=3)

0

PD, %

18% (n=8)

15% (n=4)

NE, %

2% (n=1)

4% (n=1)

DCR, %i,iii

80% (n=35)

81% (n=22)

Median DoR (months) (95% CI)i

16.8 months (5.6-NE)

16.8 months (5.6-NE)

Median PFS (months) (95% CI)i

4.4 months (3.0-7.3)

7.3 months (3.0-18.0)

Median OS (months) (95% CI)

13.5 months (10.1-16.3)

14.3 months (10.5-NE)

CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; NE, not evaluable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease

iAs assessed by BICR

iiORR is (CR + PR)

iiiDCR is (CR+PR+SD+non-CR/non-PD)

BEGONIA Arm 7 Updated Results
Updated results from the BEGONIA phase 1b/2 trial (n=61) showed datopotamab deruxtecan in combination with durvalumab, AstraZeneca’s immune checkpoint inhibitor, demonstrated an ORR of 73.6% (95% CI: 59.7-84.7) in patients with previously untreated unresectable, locally advanced or metastatic TNBC as assessed by investigator. Among the 53 evaluable patients, there were four CRs and 35 PRs. Responses were observed regardless of PD-L1 expression (low and high tumors) with 82% of patients continuing to respond at the time of data cut-off on July 22, 2022. These data were presented as a Spotlight Poster Discussion (abstract #PD11-09) at SABCS on December 8.

The safety profile of datopotamab deruxtecan in combination with durvalumab was consistent with the known safety profiles of both agents. The most common all-grade TEAEs occurring in 20% or more of patients were nausea (57.4%), stomatitis (55.7%), alopecia (45.9%), fatigue (39.3%), constipation (39.3%), rash (27.9%) and vomiting (21.3%). Serious TEAEs were observed in 10 (16.4%) patients. Treatment discontinuations due to an adverse event occurred in four patients (6.6%). Two (3.3%) cases were adjudicated as treatment-related grade 1 ILD.

Twenty-five patients (41.0%) had not received prior treatment for metastatic TNBC. Prior treatments for patients with disease progression following treatment for early-stage disease included radiotherapy (49.2%), anthracyclines (45.9%), taxanes (41.0%), platinum-based chemotherapy (14.8%), hormonal therapy (14.8%) and targeted therapy (4.9%). Seven (11.5%) patients had high PD-L1 expression (tumor area positivity [TAP]≥10%) and 53 patients (86.9%) had low PD-L1 expression (TAP<10%). At data cut-off, 45 patients remained on study treatment.

Daiichi Sankyo and AstraZeneca have a broad clinical development program for datopotamab deruxtecan in TNBC, including the recently initiated global TROPION-Breast03 phase 3 trial evaluating datopotamab deruxtecan with and without durvalumab in patients with stage 1 to 3 TNBC with residual disease after neoadjuvant therapy. The first patients were enrolled in November 2022 and are expected to be dosed in December 2022. SWOG Cancer Research Network Clinical Trials Partnerships (SWOG CTP) is the lead academic group for the trial and a key collaborator in its protocol development, US site selection and planned recruitment and analysis.

About TROPION-PanTumor01
TROPION-PanTumor01 is a first-in-human, open-label, two-part, multicenter phase 1 trial evaluating the safety and preliminary efficacy of datopotamab deruxtecan in patients with advanced solid tumors that have relapsed or are refractory to standard treatment or for which no standard treatment is available. The dose escalation portion of the trial enrolled patients with non-small cell lung cancer (NSCLC) to assess the safety and efficacy of datopotamab deruxtecan to determine the recommended dose for expansion (6 mg/kg). The dose expansion part of TROPION-PanTumor01 is enrolling several different cohorts including patients with NSCLC, TNBC, HR positive, HER2 low or negative breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, castration resistant prostate and esophageal cancer.

Safety endpoints include dose-limiting toxicities and serious adverse events. Efficacy endpoints include ORR, DoR, time to response, PFS and OS. Pharmacokinetic, biomarker and immunogenicity endpoints also are being evaluated.

About BEGONIA
BEGONIA is an open-label, two-part, multicenter phase 1b/2 trial evaluating durvalumab in combination with oncology therapies with or without paclitaxel for the first-line treatment of metastatic TNBC. Arm 7 of the trial is evaluating the safety, tolerability and preliminary efficacy of datopotamab deruxtecan in combination with durvalumab in patients with previously untreated, unresectable locally advanced or metastatic TNBC.

The primary endpoints are safety and tolerability. The secondary endpoints include investigator-assessed ORR, PFS, DoR and OS.

About Triple Negative Breast Cancer
Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide.4 More than two million breast cancer cases were diagnosed in 2020 with nearly 685,000 deaths globally.4

Approximately 15% of breast cancers are considered triple negative, which is defined by tumors that test negative for estrogen and progesterone hormone receptors (HRs) and low or negative for human epidermal growth factor 2 receptor (HER2), as determined by an immunohistochemistry (IHC) test and/or an in-situ hybridization (ISH) test.1 Tumors with HER2 expression measured as IHC 0 are considered HER2 negative and tumors with HER2 expression measured as IHC 1+ or IHC 2+/ISH- are considered HER2 low.1,5 TNBC is considered the most aggressive subtype of breast cancer.1,2 Compared to patients with other breast cancer subtypes, the prognosis for patients with metastatic TNBC is generally worse with a five-year survival rate estimated at 12% and a median overall survival rate of 12 to 18 months.1,3

TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is broadly expressed in several types of solid tumors, including approximately 80% of patients with TNBC.6,7,8 TROP2 expression is an unfavorable prognostic factor for overall survival in all types of breast cancer.8

About Datopotamab Deruxtecan (Dato-DXd)
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

A comprehensive development program called TROPION is underway globally with more than 10 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple TROP2 targetable tumors, including NSCLC, TNBC and HR positive, HER2 low or negative breast cancer. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for the manufacturing and supply of datopotamab deruxtecan.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

References:

1 National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed December 2022.
2 O’Reilly D, et al. World J Clin Oncol. 2021; 12(3):164-182.
3 Sharma P. et al. Oncologist. 2016;21(9):1050–1062.
4 Sung H, et al. CA Cancer J Clin. 2021;10.3322/caac.21660.
5 Iqbal N, et al. Mol Biol Int. 2014;852748.
6 Goldenberg D, et al. Oncotarget. 2018;9(48): 28989-29006.
7 Ambrogi F, et al. PLoS One. 2014;9(5):e96993.
8 Zaman S, et al. Onco Targets Ther. 2019;12:1781-1790.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005562/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ and Displayce Collaborate to Bring Sales Lift Measurement to Europe’s DOOH Advertising Market16.9.2025 18:00:00 CEST | Press release

NIQ, a leading consumer intelligence company, and Displayce, a pioneering specialist technology suite for Out-of-Home advertising, are collaborating to bring advanced measurement capabilities to the European DOOH market. By combining NIQ’s trusted consumer intelligence with data from Displayce’s media activation platform, advertisers can link DOOH campaigns to in-store sales performance — driving transparency and accountability across the DOOH ecosystem. NIQ has long been a trusted source of consumer purchase insights for manufacturers and retailers, capturing the buying behavior of millions of households across more than 90 countries. Now, NIQ is extending its expertise and insights into the media ecosystem, empowering advertisers and agencies with new data assets and measurement solutions to improve their understanding of consumers and drive better ROI. Through the collaboration, NIQ and Displayce are driving the DOOH ecosystem toward more addressable, transparent, and results-driven

Capcom’s Resident Evil Requiem, the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 15:00:00 CEST | Press release

– Additionally, two other Resident Evil series titles to be released for the console on the same date in step with Capcom’s multi-platform strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerou

Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production16.9.2025 15:00:00 CEST | Press release

Human insight and autonomous agents work together to transform operations, enhance efficiency, improve safety, and unlock new value across the enterprise. Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/ Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectiv

GlobalPlatform to Drive Next Phase of Growth for PSA Certified, Accelerating Security Adoption16.9.2025 15:00:00 CEST | Press release

Founded by Arm and industry partners, PSA Certified will continue to evolve under GlobalPlatform’s governance as the trusted global standard for secure connected devices GlobalPlatform announced today it will assume governance of PSA Certified, the global security certification scheme launched by Arm and key partners in 2019. In this next phase of growth, GlobalPlatform—the global standards organization for secure digital services and devices—will drive further collaboration, broader industry participation, and greater regulatory alignment for PSA Certified. Since its launch, PSA Certified has become a globally adopted framework that helps manufacturers and developers build secure connected products based on a Root of Trust. It aligns key security components—such as device identity, cryptography, attestation, and secure boot—with certification needs, regulatory requirements, and global best practices. To date, more than 250 products — spanning silicon, software, and devices—have been c

Moody’s Agentic Solutions to Automate Complex Workflows and Speed Human Decision-Making16.9.2025 14:00:00 CEST | Press release

Moody’s today announced Agentic Solutions, a groundbreaking addition to its suite of AI-powered offerings designed to transform how organizations make decisions in complex, high-stakes environments. The new solutions empower organizations to act with greater speed, precision, and confidence than ever before, reshaping how risk is decoded, opportunities are identified, and decisions are made. “For over a century, our customers have looked to Moody’s for premium data, trusted insights, and cutting-edge solutions to help them make better, more informed decisions,” said Rob Fauber, President and CEO of Moody’s. “Agentic Solutions is a natural extension of our legacy of investment and innovation – anchored in the strength of our industry leading data-estate and the depth of our people’s analytical skills. By integrating agentic capabilities into the workflows of our customers, we are supercharging the speed and precision at which we can help our customers understand risk and unlock opportun

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye